Ifp Advisors, Inc Bei Gene, Ltd. Transaction History

Ifp Advisors, Inc

$2.42 Billion
Q2 2024

A detailed history of Ifp Advisors, Inc transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Ifp Advisors, Inc holds 1,285 shares of BGNE stock, worth $249,624. This represents 0.01% of its overall portfolio holdings.

Number of Shares

1,285

Previous 973 32.07%

Holding current value

$249,624

Previous $152,000 20.39%

% of portfolio

0.01%

Previous 0.01%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 30, 2024	BUY	$129.52 - $174.32 $40,410 - $54,387	312 Added 32.07%	1,285 $183,000
Q1 2024 Jul 30, 2024	BUY	$141.8 - $181.47 $21,553 - $27,583	152 Added 18.51%	973 $152,000
Q4 2023 Jan 09, 2024	BUY	$158.67 - $201.58 $16,501 - $20,964	104 Added 14.5%	821 $148,000
Q1 2023 Apr 18, 2023	SELL	$215.53 - $274.5 $8,405 - $10,705	-39 Reduced 5.16%	717 $154,000
Q4 2022 Feb 07, 2023	SELL	$125.51 - $229.3 $502 - $917	-4 Reduced 0.53%	756 $155,000
Q3 2022 Nov 08, 2022	BUY	$131.8 - $202.24 $1,449 - $2,224	11 Added 1.47%	760 $155,000
Q2 2022 Sep 06, 2022	BUY	$121.11 - $216.05 $90,711 - $161,821	749 New	749 $153,000
Q2 2022 Aug 12, 2022	SELL	$121.11 - $216.05 $90,711 - $161,821	-749 Closed	0 $0
Q1 2022 Sep 06, 2022	BUY	$146.52 - $269.56 $15,384 - $28,303	105 Added 16.3%	749 $141,000
Q1 2022 Aug 08, 2022	BUY	$146.52 - $269.56 $22,271 - $40,973	152 Added 30.89%	644 $121,000
Q4 2021 Jan 12, 2022	SELL	$248.56 - $389.34 $248 - $389	-1 Reduced 0.2%	492 $133,000
Q3 2021 Oct 06, 2021	SELL	$249.6 - $403.14 $998 - $1,612	-4 Reduced 0.8%	493 $177,000
Q2 2021 Jul 13, 2021	SELL	$292.75 - $367.01 $585 - $734	-2 Reduced 0.4%	497 $168,000
Q1 2021 Apr 30, 2021	BUY	$260.64 - $382.12 $20,069 - $29,423	77 Added 18.25%	499 $173,000
Q4 2020 Jan 25, 2021	BUY	$221.31 - $316.61 $3,762 - $5,382	17 Added 4.2%	422 $108,000
Q3 2020 Oct 29, 2020	SELL	$189.18 - $286.44 $1,324 - $2,005	-7 Reduced 1.7%	405 $116,000
Q2 2020 Aug 05, 2020	BUY	$123.9 - $195.41 $247 - $390	2 Added 0.49%	412 $75,000
Q1 2020 May 12, 2020	SELL	$121.84 - $173.19 $243 - $346	-2 Reduced 0.49%	410 $55,000
Q4 2019 Jan 17, 2020	SELL	$115.78 - $208.34 $2,431 - $4,375	-21 Reduced 4.85%	412 $72,000
Q3 2019 Nov 07, 2019	BUY	$120.61 - $148.29 $52,224 - $64,209	433 New	433 $52,000
Q1 2019 May 15, 2019	SELL	$122.82 - $151.83 $56,128 - $69,386	-457 Closed	0 $0
Q4 2018 Jan 23, 2019	SELL	$107.01 - $175.15 $2,782 - $4,553	-26 Reduced 5.38%	457 $64,000
Q3 2018 Oct 25, 2018	BUY	$152.62 - $189.66 $64,100 - $79,657	420 Added 666.67%	483 $0
Q2 2018 Aug 07, 2018	SELL	$152.5 - $216.77 $13,725 - $19,509	-90 Reduced 58.82%	63 $0
Q1 2018 Jun 03, 2019	BUY	$97.41 - $177.22 $7,792 - $14,177	80 Added 109.59%	153 $15,000
Q1 2018 May 09, 2018	BUY	$97.41 - $177.22 $1,948 - $3,544	20 Added 37.74%	73 $0
Q4 2017 Jan 24, 2018	SELL	$79.6 - $114.73 $17,671 - $25,470	-222 Reduced 80.73%	53 $0
Q3 2017 Oct 30, 2017	BUY	$66.19 - $103.46 $18,202 - $28,451	275	275 $28,000

Others Institutions Holding BGNE

# of Institutions

249

Shares Held

45.3M

Call Options Held

292K

Put Options Held

119K

View Full List

About BeiGene, Ltd.

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $20.1B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

More about BGNE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ifp Advisors, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ifp Advisors, Inc with notifications on news.

Account